drugset
drugset / Trial / NCT04015024

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

NCT04015024 ↗

Phase 2 Unknown 30 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-randomizedSingle-groupSingle-blindTreatment

Summary

Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to evaluate the side effects,tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.

Timeline

Start
2019-07
Primary completion
2021-04
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject RUSERONTINIB Small molecule 150 mg Oral
Subject RUSERONTINIB Small molecule 200 mg Oral
Subject RUSERONTINIB Small molecule 300 mg Oral

Indications

acute myeloid leukemia